Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, and a method of coating the device with the composition, and an implantable device coated with the composition are provided.

Abstract: Disclosed herein is an aqueous emulsion. The lipid phase of the emulsion includes a blend of a therapeutically effective concentration of a lipophile, a concentration of Vitamin E TPGS, and a concentration of linoleic acid. The presence of linoleic acid increases the solubilizing affect of Vitamin E TPGS on the lipophile and thus reduces the amount of Vitamin E TPGS that would otherwise be required in the aqueous emulsion.

Abstract: A medical device for placement at a site in a patient's body and for controlling pH levels at the site in the patient's body includes one or more structural components made of a first biodegradable and/or bioabsorbable material or, alternatively, one or more structural components having a coating thereon made of a first biodegradable and/or bioabsorbable material. The device also includes a buffering agent and at least one second biodegradable and/or bioabsorbable material on or in the one or more structural components, or alternatively, on or in the coating on the one or more structural components. The at least one second biodegradable and/or bioabsorbable material encapsulates the buffering agent and the buffering agent is dispersed from the at least one second biodegradable and/or bioabsorbable material in response to hydrolysis of the first biodegradable and/or bioabsorbable material.

Abstract: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy, and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder.

Abstract: The invention provides a novel “separation marking” on a tablet as a means for assisting in the identification of a region on the tablet that is desired to be able to be broken from time to time. Said breaking allows production of smaller dosage forms known herein as tablettes. In a preferred embodiment, the separation mark will be a printed mark that is made on the tablet surface.

Abstract: A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w/v) to about 2% w/v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w/w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.

Abstract: A random or a block copolymer which includes at least one biologically compatible structural moiety and at least one biologically active moiety is disclosed. The random or block copolymer can be used for fabricating a coating for an implantable medical device such as a stent.

Abstract: This invention is about anti-fat cleansing composition for hair and scalp with an active ingredient derived from natural sources. Active ingredient used is butyl esters of fatty acids of avocado oil, which is known as 5-?-Avocuta.

Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.

Abstract: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.

Abstract: The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles.

Abstract: The solid hair wax product for treating or setting up a human hair-do or hair style contains at least one silicone-free wax, at least one hydrophobic oil that is liquid at 25° C. and at least one silicone wax with a melting point in a range of from 20 to 45° C. Preferably the silicone-free wax is a hydrocarbon wax, the hydrophobic oil is a silicone oil and the silicone wax is an alkylmethyl-dimethyl-siloxane.

Abstract: The present disclosure relates to a composition for permanently reshaping keratin fibers, such as the hair, comprising ammonium bicarbonate and at least one other alkaline agent chosen from aqueous ammonia and ammonium salts other than ammonium bicarbonate, with an ammonium molar concentration ratio of greater than 2.1, at least one non-cyclic cationic polymer, and at least one reducing agent, wherein, when aqueous ammonia is present, it is present in an amount of less than 3% by weight. Also disclosed herein is permanent-reshaping process comprising the application of this reducing composition in a first stage, followed, after a leave-in time, by the application of a fixing composition and rinsing of the keratin fibers thus treated. The present disclosure further relates to a multi-compartment device or kit comprising this reducing composition.

Abstract: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes.

Abstract: The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl, preferably in tablets dosage forms.

Abstract: A method of forming a multi-particulate dosage form using rotary granulation is described in which polyethylene oxide is employed as s binder in a rotary granulation process. A multi-particulate oral dosage form comprises a plurality of pellets, the pellets comprising a core having disposed thereon a core composition layer. The core composition layer comprises venlafaxine and a binder, wherein the binder comprises a polyethylene oxide. In other embodiments, the binder comprises a 1:2:1 bis (butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: A bioresorbable composite of a non-crystalline calcium phosphate ceramic synthesized within an encapsulating microspheres of bioresorbable polymeric material for use in bone repair and replacement is provided. Also provides are methods for producing these composites as well as porous, 3-dimensional scaffold produced by sintering together microspheres of this bioresorbable composite.

Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.